首页 > 最新文献

Clinical Epidemiology最新文献

英文 中文
Effects of Curative-Intent Treatments on Hepatocellular Carcinoma Survival in Alcohol-Related Cirrhosis: A Nationwide Study. 治疗意向治疗对酒精相关性肝硬化肝细胞癌患者生存的影响:一项全国性研究
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S393118
Frederik Kraglund, Gerda Elisabeth Villadsen, Peter Jepsen

Purpose: The aim of curative-intent treatment for hepatocellular carcinoma (HCC) is to restore the patients' survival to what it would have been, had they not developed HCC. We examined the chances of such 'statistical cure' from HCC in patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis).

Patients and methods: Using nationwide Danish healthcare registries, all patients with ALD cirrhosis who were treated for HCC in 2004-2018 were identified and included in cohorts based on initial HCC treatment. We used cure fraction analyses to estimate the chance of being statistically cured by each HCC treatment.

Results: We included 1087 patients with HCC due to ALD cirrhosis, of whom 51 (4.7%) were treated with resection and 215 (19.8%) were treated with ablation. The cure fraction, ie the fraction of patients who experienced no excess mortality from HCC, was 31.8% (95% CI: 0.0-67.5) following resection and 22.9% (95% CI: 2.6-43.2) following ablation. In patients who were still alive five years after the initial HCC treatment, the likelihood of having been statistically cured at that time was 69.0% after resection and 60.2% after ablation. For both treatments, a 90% chance of having been statistically cured was reached after seven years.

Conclusion: Based on cure fraction analyses, resection for HCC statistically cures 31.8% of patients with HCC and underlying ALD cirrhosis, while ablation statistically cures 22.9% of patients. Seven years after curative-intent treatments for HCC, surviving patients are 90% likely to be statistically cured of HCC. This information is valuable to patients and the clinicians caring for them.

目的:肝细胞癌(HCC)的治疗目的是使患者的生存率恢复到未发生HCC时的水平。我们研究了酒精相关性肝病(ALD肝硬化)肝硬化患者HCC“统计学治愈”的机会。患者和方法:使用丹麦全国医疗保健登记处,识别2004-2018年期间接受HCC治疗的所有ALD肝硬化患者,并根据初始HCC治疗将其纳入队列。我们使用治愈分数分析来估计每一种HCC治疗在统计学上治愈的机会。结果:我们纳入了1087例因ALD肝硬化导致的HCC患者,其中51例(4.7%)接受了切除治疗,215例(19.8%)接受了消融治疗。切除后的治愈率为31.8% (95% CI: 0.0-67.5),消融后的治愈率为22.9% (95% CI: 2.6-43.2)。在HCC初始治疗后仍存活5年的患者中,当时统计学上治愈的可能性在切除后为69.0%,在消融后为60.2%。两种治疗方法在7年后的治愈率都达到了90%。结论:基于治愈率分析,HCC合并ALD肝硬化患者行肝细胞癌切除术治愈率为31.8%,而消融治愈率为22.9%。在肝癌治疗7年后,存活的患者有90%的可能性被HCC治愈。这些信息对病人和照顾他们的临床医生很有价值。
{"title":"Effects of Curative-Intent Treatments on Hepatocellular Carcinoma Survival in Alcohol-Related Cirrhosis: A Nationwide Study.","authors":"Frederik Kraglund,&nbsp;Gerda Elisabeth Villadsen,&nbsp;Peter Jepsen","doi":"10.2147/CLEP.S393118","DOIUrl":"https://doi.org/10.2147/CLEP.S393118","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of curative-intent treatment for hepatocellular carcinoma (HCC) is to restore the patients' survival to what it would have been, had they not developed HCC. We examined the chances of such 'statistical cure' from HCC in patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis).</p><p><strong>Patients and methods: </strong>Using nationwide Danish healthcare registries, all patients with ALD cirrhosis who were treated for HCC in 2004-2018 were identified and included in cohorts based on initial HCC treatment. We used cure fraction analyses to estimate the chance of being statistically cured by each HCC treatment.</p><p><strong>Results: </strong>We included 1087 patients with HCC due to ALD cirrhosis, of whom 51 (4.7%) were treated with resection and 215 (19.8%) were treated with ablation. The cure fraction, ie the fraction of patients who experienced no excess mortality from HCC, was 31.8% (95% CI: 0.0-67.5) following resection and 22.9% (95% CI: 2.6-43.2) following ablation. In patients who were still alive five years after the initial HCC treatment, the likelihood of having been statistically cured at that time was 69.0% after resection and 60.2% after ablation. For both treatments, a 90% chance of having been statistically cured was reached after seven years.</p><p><strong>Conclusion: </strong>Based on cure fraction analyses, resection for HCC statistically cures 31.8% of patients with HCC and underlying ALD cirrhosis, while ablation statistically cures 22.9% of patients. Seven years after curative-intent treatments for HCC, surviving patients are 90% likely to be statistically cured of HCC. This information is valuable to patients and the clinicians caring for them.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/68/clep-15-39.PMC9831002.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9092275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System. 美国医疗系统从ICD-9向ICD-10过渡中高维倾向评分程序的适应性
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S405165
Amir Sarayani, Joshua D Brown, Christian Hampp, William T Donahoo, Almut G Winterstein

Background: High-Dimensional Propensity Score procedure (HDPS) is a data-driven approach to assist control for confounding in pharmacoepidemiologic research. The transition to the International Classification of Disease (ICD-9/10) in the US health system may pose uncertainty in applying the HDPS procedure.

Methods: We assembled a base cohort of patients in MarketScan® Commercial Claims Database who had newly initiated celecoxib or traditional NSAIDs to compare gastrointestinal bleeding risk. We then created bootstrapped hypothetical cohorts from the base cohort with predefined patient selection patterns from the ICD eras. Three strategies for HDPS deployment were tested: 1) split the cohort by ICD era, deploy HDPS twice, and pool the relative risks (pooled RR), 2) consider codes from each ICD era as a separate data dimension and deploy HDPS in the entire cohort (data dimensions) and 3) map ICD codes from both eras to Clinical Classifications Software (CCS) concepts before deploying HDPS in the entire cohort (CCS mapping). We calculated percent bias and root-mean-squared error to compare the strategies.

Results: A similar bias reduction was observed in cohorts where patient selection pattern from each ICD era was comparable between the exposure groups. In the presence of considerable disparity in patient selection, we observed a bimodal distribution of propensity scores in the data dimensions strategy, indicating instrument-like covariates. Moreover, the CCS mapping strategy resulted in at least 30% less bias than pooled RR and data dimensions strategies (RMSE: 0.14, 0.19, 0.21, respectively) in this scenario.

Conclusion: Mapping ICD codes to a stable terminology like CCS serves as a helpful strategy to reduce residual bias when deploying HDPS in pharmacoepidemiologic studies spanning both ICD eras.

背景:高维倾向评分程序(HDPS)是一种数据驱动的方法,以协助控制药物流行病学研究中的混杂。美国卫生系统向国际疾病分类(ICD-9/10)的过渡可能会给应用HDPS程序带来不确定性。方法:我们在MarketScan®商业索赔数据库中收集了新开始使用塞来昔布或传统非甾体抗炎药的患者的基本队列,以比较胃肠道出血风险。然后,我们根据ICD时代预定义的患者选择模式,从基础队列中创建了自举假设队列。测试了三种部署HDPS的策略:1)按ICD时代划分队列,部署两次HDPS,并汇集相对风险(合并RR); 2)将每个ICD时代的代码视为单独的数据维度,并在整个队列中部署HDPS(数据维度);3)在整个队列中部署HDPS之前,将两个时代的ICD代码映射到临床分类软件(CCS)概念(CCS映射)。我们计算了百分比偏差和均方根误差来比较这些策略。结果:在每个ICD时代的患者选择模式在暴露组之间具有可比性的队列中观察到类似的偏倚减少。在患者选择中存在相当大的差异,我们观察到数据维度策略中倾向得分的双峰分布,表明工具样协变量。此外,在这种情况下,CCS映射策略比混合RR和数据维度策略至少减少30%的偏差(RMSE分别为0.14、0.19和0.21)。结论:在跨越两个ICD时代的药物流行病学研究中部署HDPS时,将ICD代码映射到像CCS这样的稳定术语是减少残留偏差的有用策略。
{"title":"Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System.","authors":"Amir Sarayani,&nbsp;Joshua D Brown,&nbsp;Christian Hampp,&nbsp;William T Donahoo,&nbsp;Almut G Winterstein","doi":"10.2147/CLEP.S405165","DOIUrl":"https://doi.org/10.2147/CLEP.S405165","url":null,"abstract":"<p><strong>Background: </strong>High-Dimensional Propensity Score procedure (HDPS) is a data-driven approach to assist control for confounding in pharmacoepidemiologic research. The transition to the International Classification of Disease (ICD-9/10) in the US health system may pose uncertainty in applying the HDPS procedure.</p><p><strong>Methods: </strong>We assembled a base cohort of patients in MarketScan<sup>®</sup> Commercial Claims Database who had newly initiated celecoxib or traditional NSAIDs to compare gastrointestinal bleeding risk. We then created bootstrapped hypothetical cohorts from the base cohort with predefined patient selection patterns from the ICD eras. Three strategies for HDPS deployment were tested: 1) split the cohort by ICD era, deploy HDPS twice, and pool the relative risks (pooled RR), 2) consider codes from each ICD era as a separate data dimension and deploy HDPS in the entire cohort (data dimensions) and 3) map ICD codes from both eras to Clinical Classifications Software (CCS) concepts before deploying HDPS in the entire cohort (CCS mapping). We calculated percent bias and root-mean-squared error to compare the strategies.</p><p><strong>Results: </strong>A similar bias reduction was observed in cohorts where patient selection pattern from each ICD era was comparable between the exposure groups. In the presence of considerable disparity in patient selection, we observed a bimodal distribution of propensity scores in the data dimensions strategy, indicating instrument-like covariates. Moreover, the CCS mapping strategy resulted in at least 30% less bias than pooled RR and data dimensions strategies (RMSE: 0.14, 0.19, 0.21, respectively) in this scenario.</p><p><strong>Conclusion: </strong>Mapping ICD codes to a stable terminology like CCS serves as a helpful strategy to reduce residual bias when deploying HDPS in pharmacoepidemiologic studies spanning both ICD eras.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/00/clep-15-645.PMC10237200.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9581658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Dispensing Patterns of Inhalation Medication in Young Adult Asthma: An Inception Cohort Study. 青少年哮喘患者吸入药物的实际分配模式:一项初始队列研究。
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S410036
Irene Mommers, Job F M van Boven, Catharina C M Schuiling-Veninga, Jens H J Bos, Marten Koetsier, Eelko Hak, Maarten J Bijlsma

Purpose: The Global Initiative for Asthma (GINA) suggests a step-wise approach for pharmacological treatment of asthma. Valid study of real-world treatment patterns using dispensing databases includes proper measurement of medication adherence. We aim to explore such patterns by applying a time-varying proportion of days covered (tPDC)-based algorithm.

Patients and methods: We designed a retrospective inception cohort study using the University of Groningen IADB.nl community pharmacy dispensing database. Included were 19,184 young adults who initiated asthma medication anywhere between 1994 and 2021, in the Netherlands. Main treatment steps were defined as: 1 - SABA/ICS-formoterol as needed, 2 - low dose ICS, 3 - low dose ICS + LABA or tiotropium, or intermediate dose ICS, 4 - intermediate to high dose ICS + LABA or tiotropium, triple therapy, or high dose ICS, 5 - treatment prescribed by a specialist. Changes in treatment steps were determined using a time-varying proportion of days covered (tPDC)-based algorithm. Individual drug treatment trajectories were visualized over time using a lasagna plot.

Results: At initiation, of the 19,184 included individuals, 52%, 7%, 15%, 16%, and 10% started treatment in steps 1 to 5, respectively. The median (IQR) follow-up time was 3 (1-7) years. Median (IQR) number of switches was 1 (0-3). Comparing starting step to last observed step, 37% never switched between treatment steps, 20% of individuals stepped down and 22% stepped up.

Conclusion: The low proportion of treatment switches between steps indicates that tailoring of treatment to patients' needs might be suboptimal. The tPDC-based algorithm functions well in translating dispensing data into continuous drug-utilization data, enabling a more granular assessment of treatment patterns among asthma patients.

目的:全球哮喘倡议(GINA)提出了一种循序渐进的哮喘药物治疗方法。使用配药数据库对真实世界的治疗模式进行有效的研究,包括对药物依从性的适当测量。我们的目标是通过应用基于时间变化的覆盖天数比例(tPDC)的算法来探索这种模式。患者和方法:我们使用格罗宁根大学IADB设计了一项回顾性初始队列研究。社区药房调剂数据库。其中包括荷兰在1994年至2021年间开始服用哮喘药物的19184名年轻人。主要治疗步骤定义为:1 - SABA/ICS-福莫特罗根据需要,2 -低剂量ICS, 3 -低剂量ICS + LABA或噻托溴铵,或中剂量ICS, 4 -中高剂量ICS + LABA或噻托溴铵,三联治疗,或高剂量ICS, 5 -专家规定的治疗。使用基于时变天数比例(tPDC)的算法确定治疗步骤的变化。个体药物治疗轨迹随着时间的推移使用千层面图可视化。结果:在开始时,19184名纳入的个体中,分别有52%,7%,15%,16%和10%在步骤1至5中开始治疗。中位(IQR)随访时间为3(1-7)年。开关中位数(IQR)为1(0-3)。将开始步骤与最后观察步骤进行比较,37%的人从未在治疗步骤之间切换,20%的人降级,22%的人升级。结论:低比例的治疗切换之间的步骤表明,量身定制的治疗,以病人的需要可能是不理想的。基于tpdc的算法可以很好地将调剂数据转换为连续的药物利用数据,从而对哮喘患者的治疗模式进行更细致的评估。
{"title":"Real-World Dispensing Patterns of Inhalation Medication in Young Adult Asthma: An Inception Cohort Study.","authors":"Irene Mommers,&nbsp;Job F M van Boven,&nbsp;Catharina C M Schuiling-Veninga,&nbsp;Jens H J Bos,&nbsp;Marten Koetsier,&nbsp;Eelko Hak,&nbsp;Maarten J Bijlsma","doi":"10.2147/CLEP.S410036","DOIUrl":"https://doi.org/10.2147/CLEP.S410036","url":null,"abstract":"<p><strong>Purpose: </strong>The Global Initiative for Asthma (GINA) suggests a step-wise approach for pharmacological treatment of asthma. Valid study of real-world treatment patterns using dispensing databases includes proper measurement of medication adherence. We aim to explore such patterns by applying a time-varying proportion of days covered (tPDC)-based algorithm.</p><p><strong>Patients and methods: </strong>We designed a retrospective inception cohort study using the University of Groningen IADB.nl community pharmacy dispensing database. Included were 19,184 young adults who initiated asthma medication anywhere between 1994 and 2021, in the Netherlands. Main treatment steps were defined as: 1 - SABA/ICS-formoterol as needed, 2 - low dose ICS, 3 - low dose ICS + LABA or tiotropium, or intermediate dose ICS, 4 - intermediate to high dose ICS + LABA or tiotropium, triple therapy, or high dose ICS, 5 - treatment prescribed by a specialist. Changes in treatment steps were determined using a time-varying proportion of days covered (tPDC)-based algorithm. Individual drug treatment trajectories were visualized over time using a lasagna plot.</p><p><strong>Results: </strong>At initiation, of the 19,184 included individuals, 52%, 7%, 15%, 16%, and 10% started treatment in steps 1 to 5, respectively. The median (IQR) follow-up time was 3 (1-7) years. Median (IQR) number of switches was 1 (0-3). Comparing starting step to last observed step, 37% never switched between treatment steps, 20% of individuals stepped down and 22% stepped up.</p><p><strong>Conclusion: </strong>The low proportion of treatment switches between steps indicates that tailoring of treatment to patients' needs might be suboptimal. The tPDC-based algorithm functions well in translating dispensing data into continuous drug-utilization data, enabling a more granular assessment of treatment patterns among asthma patients.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/74/clep-15-721.PMC10276997.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9668685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Drug Safety Signal Detection and Triage System Integrating Sequence Symmetry Analysis and Tree-Based Scan Statistics with Longitudinal Data. 结合序列对称分析和基于树的扫描统计与纵向数据的新型药物安全信号检测与分诊系统。
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S395922
Miyuki Hsing-Chun Hsieh, Hsun-Yin Liang, Chih-Ying Tsai, Yu-Ting Tseng, Pi-Hui Chao, Wei-I Huang, Wen-Wen Chen, Swu-Jane Lin, Edward Chia-Cheng Lai

Purpose: Development and evaluation of a drug-safety signal detection system integrating data-mining tools in longitudinal data is essential. This study aimed to construct a new triage system using longitudinal data for drug-safety signal detection, integrating data-mining tools, and evaluate adaptability of such system.

Patients and methods: Based on relevant guidelines and structural frameworks in Taiwan's pharmacovigilance system, we constructed a triage system integrating sequence symmetry analysis (SSA) and tree-based scan statistics (TreeScan) as data-mining tools for detecting safety signals. We conducted an exploratory analysis utilizing Taiwan's National Health Insurance Database and selecting two drug classes (sodium-glucose co-transporter-2 inhibitors (SGLT2i) and non-fluorinated quinolones (NFQ)) as chronic and episodic treatment respectively, as examples to test feasibility of the system.

Results: Under the proposed system, either cohort-based or self-controlled mining with SSA and TreeScan was selected, based on whether the screened drug had an appropriate comparator. All detected alerts were further classified as known adverse drug reactions (ADRs), events related to other causes or potential signals from the triage algorithm, building on existing drug labels and clinical judgement. Exploratory analysis revealed greater numbers of signals for NFQ with a relatively low proportion of known ADRs; most were related to indication, patient characteristics or bias. No safety signals were found. By contrast, most SGLT2i signals were known ADRs or events related to patient characteristics. Four were potential signals warranting further investigation.

Conclusion: The proposed system facilitated active and systematic screening to detect and classify potential safety signals. Countries with real-world longitudinal data could adopt it to streamline drug-safety surveillance.

目的:在纵向数据中集成数据挖掘工具的药物安全信号检测系统的开发和评价是必要的。本研究旨在整合数据挖掘工具,构建一种基于纵向数据的药物安全信号检测分诊新系统,并评估该系统的适应性。患者与方法:基于台湾药物警戒系统的相关指南和结构框架,我们构建了一个结合序列对称分析(SSA)和基于树的扫描统计(TreeScan)作为检测安全信号的数据挖掘工具的分诊系统。我们利用台湾的国民健康保险数据库进行了探索性分析,并选择两种药物类别(钠-葡萄糖共转运蛋白-2抑制剂(SGLT2i)和无氟喹诺酮类(NFQ))分别作为慢性和间歇性治疗,以验证该系统的可行性。结果:在拟议的系统下,根据筛选药物是否有合适的比较物,选择基于队列的挖掘或SSA和TreeScan的自我控制挖掘。根据现有药物标签和临床判断,将所有检测到的警报进一步分类为已知药物不良反应(adr)、与其他原因相关的事件或来自分诊算法的潜在信号。探索性分析显示,NFQ的信号数量较多,而已知adr的比例相对较低;大多数与适应症、患者特征或偏倚有关。没有发现安全信号。相比之下,大多数SGLT2i信号是已知的不良反应或与患者特征相关的事件。其中4个是需要进一步调查的潜在信号。结论:该系统有助于主动和系统的筛选,以检测和分类潜在的安全信号。拥有真实世界纵向数据的国家可以采用它来简化药物安全监测。
{"title":"A New Drug Safety Signal Detection and Triage System Integrating Sequence Symmetry Analysis and Tree-Based Scan Statistics with Longitudinal Data.","authors":"Miyuki Hsing-Chun Hsieh,&nbsp;Hsun-Yin Liang,&nbsp;Chih-Ying Tsai,&nbsp;Yu-Ting Tseng,&nbsp;Pi-Hui Chao,&nbsp;Wei-I Huang,&nbsp;Wen-Wen Chen,&nbsp;Swu-Jane Lin,&nbsp;Edward Chia-Cheng Lai","doi":"10.2147/CLEP.S395922","DOIUrl":"https://doi.org/10.2147/CLEP.S395922","url":null,"abstract":"<p><strong>Purpose: </strong>Development and evaluation of a drug-safety signal detection system integrating data-mining tools in longitudinal data is essential. This study aimed to construct a new triage system using longitudinal data for drug-safety signal detection, integrating data-mining tools, and evaluate adaptability of such system.</p><p><strong>Patients and methods: </strong>Based on relevant guidelines and structural frameworks in Taiwan's pharmacovigilance system, we constructed a triage system integrating sequence symmetry analysis (SSA) and tree-based scan statistics (TreeScan) as data-mining tools for detecting safety signals. We conducted an exploratory analysis utilizing Taiwan's National Health Insurance Database and selecting two drug classes (sodium-glucose co-transporter-2 inhibitors (SGLT2i) and non-fluorinated quinolones (NFQ)) as chronic and episodic treatment respectively, as examples to test feasibility of the system.</p><p><strong>Results: </strong>Under the proposed system, either cohort-based or self-controlled mining with SSA and TreeScan was selected, based on whether the screened drug had an appropriate comparator. All detected alerts were further classified as known adverse drug reactions (ADRs), events related to other causes or potential signals from the triage algorithm, building on existing drug labels and clinical judgement. Exploratory analysis revealed greater numbers of signals for NFQ with a relatively low proportion of known ADRs; most were related to indication, patient characteristics or bias. No safety signals were found. By contrast, most SGLT2i signals were known ADRs or events related to patient characteristics. Four were potential signals warranting further investigation.</p><p><strong>Conclusion: </strong>The proposed system facilitated active and systematic screening to detect and classify potential safety signals. Countries with real-world longitudinal data could adopt it to streamline drug-safety surveillance.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/2a/clep-15-91.PMC9868282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10623228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prognostic Value of Post-Operative C-Reactive Protein-Based Inflammatory Biomarkers in Colorectal Cancer Patients: Systematic Review and Meta-Analysis. 结直肠癌患者术后基于c反应蛋白的炎症生物标志物的预后价值:系统评价和荟萃分析
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S415171
Tafirenyika Gwenzi, Anna Zhu, Petra Schrotz-King, Ben Schöttker, Michael Hoffmeister, Dominic Edelmann, Hermann Brenner

Post-operative inflammation in cancer patients can be modulated by drugs and diets, but evidence on its prognostic role, which would be crucial for personalized treatment and surveillance schemes, remains rather limited. We aimed to systematically review and meta-analyse studies on the prognostic value of post-operative C-reactive protein (CRP)-based inflammatory biomarkers among patients with colorectal cancer (CRC) (PROSPERO#: CRD42022293832). PubMed, Web of Science and Cochrane databases were searched until February 2023. Studies reporting associations between post-operative CRP, Glasgow Prognostic Score (GPS) or modified Glasgow Prognostic Score (mGPS) with overall survival (OS), CRC-specific survival (CSS) and recurrence-free survival (RFS) were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the predictor-outcome associations were pooled using R-software, version 4.2. Sixteen studies (n = 6079) were included in the meta-analyses. Elevated post-operative CRP was a predictor of poor OS, CSS and RFS compared with low CRP levels [HR (95% CI): 1.72 (1.32-2.25); 1.63 (1.30-2.05); 2.23 (1.44-3.47), respectively]. A unit increase in post-operative GPS predicted poor OS [HR (95% Cl): 1.31 (1.14-1.51)]. Moreover, a unit increase in post-operative mGPS was associated with poor OS and CSS [HR (95% Cl): 1.93 (1.37-2.72); 3.16 (1.48-6.76), respectively]. Post-operative CRP-based inflammatory biomarkers have a significant prognostic role for patients with CRC. Prognostic value of these easy-to-obtain routine measurements thereby seems to outperform most of the much more complex blood- or tissue-based predictors in the current focus of multi-omics-based research. Future studies should validate our findings, establish optimal time for biomarker assessment and determine clinically useful cut-off values of these biomarkers for post-operative risk-stratification and treatment-response monitoring.

癌症患者术后炎症可以通过药物和饮食调节,但其预后作用的证据仍然相当有限,这对个性化治疗和监测方案至关重要。我们旨在系统回顾和荟萃分析结直肠癌(CRC)患者术后基于c反应蛋白(CRP)的炎症生物标志物的预后价值研究(PROSPERO#: CRD42022293832)。PubMed、Web of Science和Cochrane数据库被检索到2023年2月。研究报告了术后CRP、格拉斯哥预后评分(GPS)或改良格拉斯哥预后评分(mGPS)与总生存期(OS)、crc特异性生存期(CSS)和无复发生存期(RFS)之间的关系。风险比(hr)和95%可信区间(ci)的预测结果关联使用r软件,版本4.2进行汇总。16项研究(n = 6079)被纳入meta分析。与低CRP水平相比,术后CRP升高是不良OS、CSS和RFS的预测因子[HR (95% CI): 1.72 (1.32-2.25);1.63 (1.30 - -2.05);2.23(1.44-3.47)]。术后GPS单位增加预示着不良的OS [HR (95% Cl): 1.31(1.14-1.51)]。此外,术后mGPS单位增加与不良OS和CSS相关[HR (95% Cl): 1.93 (1.37-2.72);3.16(分别为1.48 ~ 6.76)。术后基于crp的炎症生物标志物对结直肠癌患者的预后有重要作用。因此,在当前多组学研究的重点中,这些易于获得的常规测量的预测价值似乎优于大多数更复杂的基于血液或组织的预测指标。未来的研究应该验证我们的发现,确定生物标志物评估的最佳时间,并确定这些生物标志物在术后风险分层和治疗反应监测中的临床有用临界值。
{"title":"Prognostic Value of Post-Operative C-Reactive Protein-Based Inflammatory Biomarkers in Colorectal Cancer Patients: Systematic Review and Meta-Analysis.","authors":"Tafirenyika Gwenzi,&nbsp;Anna Zhu,&nbsp;Petra Schrotz-King,&nbsp;Ben Schöttker,&nbsp;Michael Hoffmeister,&nbsp;Dominic Edelmann,&nbsp;Hermann Brenner","doi":"10.2147/CLEP.S415171","DOIUrl":"https://doi.org/10.2147/CLEP.S415171","url":null,"abstract":"<p><p>Post-operative inflammation in cancer patients can be modulated by drugs and diets, but evidence on its prognostic role, which would be crucial for personalized treatment and surveillance schemes, remains rather limited. We aimed to systematically review and meta-analyse studies on the prognostic value of post-operative C-reactive protein (CRP)-based inflammatory biomarkers among patients with colorectal cancer (CRC) (PROSPERO#: CRD42022293832). PubMed, Web of Science and Cochrane databases were searched until February 2023. Studies reporting associations between post-operative CRP, Glasgow Prognostic Score (GPS) or modified Glasgow Prognostic Score (mGPS) with overall survival (OS), CRC-specific survival (CSS) and recurrence-free survival (RFS) were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the predictor-outcome associations were pooled using R-software, version 4.2. Sixteen studies (n = 6079) were included in the meta-analyses. Elevated post-operative CRP was a predictor of poor OS, CSS and RFS compared with low CRP levels [HR (95% CI): 1.72 (1.32-2.25); 1.63 (1.30-2.05); 2.23 (1.44-3.47), respectively]. A unit increase in post-operative GPS predicted poor OS [HR (95% Cl): 1.31 (1.14-1.51)]. Moreover, a unit increase in post-operative mGPS was associated with poor OS and CSS [HR (95% Cl): 1.93 (1.37-2.72); 3.16 (1.48-6.76), respectively]. Post-operative CRP-based inflammatory biomarkers have a significant prognostic role for patients with CRC. Prognostic value of these easy-to-obtain routine measurements thereby seems to outperform most of the much more complex blood- or tissue-based predictors in the current focus of multi-omics-based research. Future studies should validate our findings, establish optimal time for biomarker assessment and determine clinically useful cut-off values of these biomarkers for post-operative risk-stratification and treatment-response monitoring.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/6f/clep-15-795.PMC10314753.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk of Obesity Among Children Aged 2-6 Years Who Had Prolonged Screen Time in Taiwan: A Nationwide Cross-Sectional Study. 台湾2-6岁儿童长时间使用萤幕之肥胖风险:一项全国性横断面研究。
IF 3.9 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S382956
Rui-Yu Chang, Ta-Liang Chen, Chun-Chieh Yeh, Ching-Hsiang Chen, Qiao-Wen Wang, Thomas Toung, Chien-Chang Liao

Objective: To evaluate the risk of obesity in preschool children with prolonged screen time in Taiwan.

Methods: Using a nationwide survey with random sampling, we collected information on 8378 preschool children aged 2-6 years among 206 preschools in Taiwan from 2016 to 2019. Socioeconomic data, body mass index, and lifestyle of the preschool children and their caregivers were compared among the groups of preschool children who had moderate and prolonged daily screen time. We used multiple log-binomial regression models to calculate the adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs) of obesity associated with prolonged screen time.

Results: The prevalence of obesity in the preschool children was 13.1%, and the average screen time was 104.6 minutes. Children's age, sleep hours, outdoor play time, sugar intake, snack eating before dinner, sleep disturbance, and obesity, as well as caregiver's sex, age, education, screen time, exercise time and parent obesity were factors related to high screen time for preschool children. Compared with children with moderate screen time, children with prolonged screen time had a higher risk of obesity (PR, 1.45; 95% CI, 1.18-1.79). With a 60-minute increase in screen time, the risk of obesity increased, with an PR of 1.10 (95% CI, 1.03-1.17).

Conclusion: Preschool children with prolonged screen time had an increased risk of obesity in Taiwan. Interventions may be needed for this very susceptible population.

目的:探讨台湾学龄前儿童屏幕时间延长的肥胖风险。方法:采用全国随机抽样调查的方法,收集2016 - 2019年台湾地区206所幼儿园2-6岁学龄前儿童8378名的资料。比较了学龄前儿童及其照顾者的社会经济数据、体重指数和生活方式,这些数据来自于每日屏幕时间适中和延长的学龄前儿童组。我们使用多个对数二项回归模型来计算肥胖与屏幕时间延长相关的调整患病率(pr)和95%置信区间(ci)。结果:学龄前儿童肥胖症患病率为13.1%,平均屏幕时间为104.6分钟。儿童年龄、睡眠时间、户外游戏时间、糖摄入量、餐前零食摄入、睡眠障碍、肥胖以及照顾者的性别、年龄、教育程度、屏幕时间、运动时间和父母肥胖是学龄前儿童高屏幕时间的相关因素。与屏幕时间适中的儿童相比,屏幕时间较长的儿童肥胖的风险更高(PR, 1.45;95% ci, 1.18-1.79)。随着屏幕时间增加60分钟,肥胖的风险增加,PR为1.10 (95% CI, 1.03-1.17)。结论:台湾学龄前儿童屏幕时间越长,肥胖风险越高。可能需要对这些非常易感的人群进行干预。
{"title":"Risk of Obesity Among Children Aged 2-6 Years Who Had Prolonged Screen Time in Taiwan: A Nationwide Cross-Sectional Study.","authors":"Rui-Yu Chang,&nbsp;Ta-Liang Chen,&nbsp;Chun-Chieh Yeh,&nbsp;Ching-Hsiang Chen,&nbsp;Qiao-Wen Wang,&nbsp;Thomas Toung,&nbsp;Chien-Chang Liao","doi":"10.2147/CLEP.S382956","DOIUrl":"https://doi.org/10.2147/CLEP.S382956","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the risk of obesity in preschool children with prolonged screen time in Taiwan.</p><p><strong>Methods: </strong>Using a nationwide survey with random sampling, we collected information on 8378 preschool children aged 2-6 years among 206 preschools in Taiwan from 2016 to 2019. Socioeconomic data, body mass index, and lifestyle of the preschool children and their caregivers were compared among the groups of preschool children who had moderate and prolonged daily screen time. We used multiple log-binomial regression models to calculate the adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs) of obesity associated with prolonged screen time.</p><p><strong>Results: </strong>The prevalence of obesity in the preschool children was 13.1%, and the average screen time was 104.6 minutes. Children's age, sleep hours, outdoor play time, sugar intake, snack eating before dinner, sleep disturbance, and obesity, as well as caregiver's sex, age, education, screen time, exercise time and parent obesity were factors related to high screen time for preschool children. Compared with children with moderate screen time, children with prolonged screen time had a higher risk of obesity (PR, 1.45; 95% CI, 1.18-1.79). With a 60-minute increase in screen time, the risk of obesity increased, with an PR of 1.10 (95% CI, 1.03-1.17).</p><p><strong>Conclusion: </strong>Preschool children with prolonged screen time had an increased risk of obesity in Taiwan. Interventions may be needed for this very susceptible population.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/b4/clep-15-165.PMC9936874.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9490890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Validated Register-Based Algorithm to Identify Patients Diagnosed with Recurrence of Surgically Treated Stage I Lung Cancer in Denmark. 一种有效的基于注册的算法来识别丹麦手术治疗的I期肺癌复发患者。
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S396738
Linda Aagaard Rasmussen, Niels Lyhne Christensen, Anne Winther-Larsen, Susanne Oksbjerg Dalton, Line Flytkjær Virgilsen, Henry Jensen, Peter Vedsted

Introduction: Recurrence of cancer is not routinely registered in Danish national health registers. This study aimed to develop and validate a register-based algorithm to identify patients diagnosed with recurrent lung cancer and to estimate the accuracy of the identified diagnosis date.

Material and methods: Patients with early-stage lung cancer treated with surgery were included in the study. Recurrence indicators were diagnosis and procedure codes recorded in the Danish National Patient Register and pathology results recorded in the Danish National Pathology Register. Information from CT scans and medical records served as the gold standard to assess the accuracy of the algorithm.

Results: The final population consisted of 217 patients; 72 (33%) had recurrence according to the gold standard. The median follow-up time since primary lung cancer diagnosis was 29 months (interquartile interval: 18-46). The algorithm for identifying a recurrence reached a sensitivity of 83.3% (95% CI: 72.7-91.1), a specificity of 93.8% (95% CI: 88.5-97.1), and a positive predictive value of 87.0% (95% CI: 76.7-93.9). The algorithm identified 70% of the recurrences within 60 days of the recurrence date registered by the gold standard method. The positive predictive value of the algorithm decreased to 70% when the algorithm was simulated in a population with a recurrence rate of 15%.

Conclusion: The proposed algorithm demonstrated good performance in a population with 33% recurrences over a median of 29 months. It can be used to identify patients diagnosed with recurrent lung cancer, and it may be a valuable tool for future research in this field. However, a lower positive predictive value is seen when applying the algorithm in populations with low recurrence rates.

简介:癌症复发在丹麦国家健康登记册中没有常规登记。本研究旨在开发和验证一种基于注册的算法,以识别被诊断为复发性肺癌的患者,并估计识别诊断日期的准确性。材料与方法:采用手术治疗的早期肺癌患者为研究对象。复发指标是丹麦国家患者登记册上记录的诊断和程序代码以及丹麦国家病理登记册上记录的病理结果。CT扫描和医疗记录的信息是评估算法准确性的金标准。结果:最终人群包括217例患者;72例(33%)复发率符合金标准。自原发性肺癌诊断后的中位随访时间为29个月(四分位数间隔:18-46)。识别复发的算法灵敏度为83.3% (95% CI: 72.7-91.1),特异性为93.8% (95% CI: 88.5-97.1),阳性预测值为87.0% (95% CI: 76.7-93.9)。该算法在金标准法记录的复发日期后60天内识别出70%的复发。当算法在复发率为15%的人群中模拟时,算法的阳性预测值下降到70%。结论:该算法在平均29个月复发率为33%的人群中表现良好。它可以用于识别诊断为复发性肺癌的患者,并可能为该领域的未来研究提供有价值的工具。然而,当将该算法应用于低复发率的人群时,可以看到较低的阳性预测值。
{"title":"A Validated Register-Based Algorithm to Identify Patients Diagnosed with Recurrence of Surgically Treated Stage I Lung Cancer in Denmark.","authors":"Linda Aagaard Rasmussen,&nbsp;Niels Lyhne Christensen,&nbsp;Anne Winther-Larsen,&nbsp;Susanne Oksbjerg Dalton,&nbsp;Line Flytkjær Virgilsen,&nbsp;Henry Jensen,&nbsp;Peter Vedsted","doi":"10.2147/CLEP.S396738","DOIUrl":"https://doi.org/10.2147/CLEP.S396738","url":null,"abstract":"<p><strong>Introduction: </strong>Recurrence of cancer is not routinely registered in Danish national health registers. This study aimed to develop and validate a register-based algorithm to identify patients diagnosed with recurrent lung cancer and to estimate the accuracy of the identified diagnosis date.</p><p><strong>Material and methods: </strong>Patients with early-stage lung cancer treated with surgery were included in the study. Recurrence indicators were diagnosis and procedure codes recorded in the Danish National Patient Register and pathology results recorded in the Danish National Pathology Register. Information from CT scans and medical records served as the gold standard to assess the accuracy of the algorithm.</p><p><strong>Results: </strong>The final population consisted of 217 patients; 72 (33%) had recurrence according to the gold standard. The median follow-up time since primary lung cancer diagnosis was 29 months (interquartile interval: 18-46). The algorithm for identifying a recurrence reached a sensitivity of 83.3% (95% CI: 72.7-91.1), a specificity of 93.8% (95% CI: 88.5-97.1), and a positive predictive value of 87.0% (95% CI: 76.7-93.9). The algorithm identified 70% of the recurrences within 60 days of the recurrence date registered by the gold standard method. The positive predictive value of the algorithm decreased to 70% when the algorithm was simulated in a population with a recurrence rate of 15%.</p><p><strong>Conclusion: </strong>The proposed algorithm demonstrated good performance in a population with 33% recurrences over a median of 29 months. It can be used to identify patients diagnosed with recurrent lung cancer, and it may be a valuable tool for future research in this field. However, a lower positive predictive value is seen when applying the algorithm in populations with low recurrence rates.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/d6/clep-15-251.PMC9986467.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9082418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Positive Predictive Value of Pediatric Stroke Diagnoses in Administrative Data: A Retrospective Validation Study. 行政资料中儿童脑卒中诊断的积极预测价值:一项回顾性验证研究。
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S414913
Julie Brix Bindslev, Soeren Paaske Johnsen, Klaus Hansen, Jan Brink Valentin, Christina Engel Hoei-Hansen, Thomas Truelsen

Background: This retrospective cohort study aimed to examine the positive predictive value (PPV) of pediatric stroke diagnoses in the Danish National Registry of Patients (DNRP) and the impact of different stroke definitions on the PPV.

Methods: We included children registered with a stroke or stroke-related diagnosis in the DNRP between January 2017 through December 2020. Two assessors reviewed medical records and validated cases according to the American Heart and American Stroke Association (AHA/ASA) stroke definition. The level of interrater agreement was examined using kappa statistics. Validation by the AHA/ASA definition was compared with validation according to the definition in the International Classification of Disease 11th version (ICD-11) and the World Health Organization's definition.

Results: Stroke was confirmed in 120 of 309 included children, yielding an overall PPV of 0.39 (95% CI: 0.33-0.45). PPV varied across stroke subtypes from 0.83 (95% CI: 0.71-0.92) for ischemic stroke (AIS), 0.57 (95% CI: 0.37-0.76) for unspecified stroke, 0.42 (95% CI: 0.33-0.52) for intracerebral hemorrhage (ICH) to 0.31 (95% CI: 0.55-0.98) and 0.07 (95% CI: 0.01-0.22) for cerebral venous thrombosis and subarachnoid hemorrhage (SAH), respectively. Most non-confirmed ICH and SAH diagnoses were in children with traumatic intracranial hemorrhages (36 and 66% respectively). Among 70 confirmed AIS cases, 25 (36%) were identified in non-AIS code groups. PPV varied significantly across stroke definitions with the highest for the AHA/ASA definition (PPV = 0.39, 95% CI: 0.34-0.45) and the lowest for the WHO definition (PPV = 0.29, 95% CI: 0.24-0.34). Correspondingly, the incidence of pediatric AIS per 100.000 person-years changed from 1.5 for the AHA/ASA definition to 1.2 for ICD-11 and 1.0 for the WHO-definition. The overall interrater agreement was considered excellent (κ=0.85).

Conclusion: After validation, stroke was confirmed in only half of the children registered in the DNRP with a stroke-specific diagnosis. Non-validated administrative data should be used with caution in pediatric stroke research. Pediatric stroke incidence rates may vary markedly depending on which stroke definition is used.

背景:本回顾性队列研究旨在研究丹麦国家患者登记册(DNRP)中儿童卒中诊断的阳性预测值(PPV)以及不同卒中定义对PPV的影响。方法:我们纳入了2017年1月至2020年12月期间在DNRP中登记为卒中或卒中相关诊断的儿童。两名评估人员根据美国心脏和美国中风协会(AHA/ASA)中风定义审查了医疗记录并验证了病例。使用kappa统计来检验翻译人员的一致性水平。将AHA/ASA定义的有效性与国际疾病分类第11版(ICD-11)和世界卫生组织定义的有效性进行比较。结果:309名纳入的儿童中有120名卒中确诊,总PPV为0.39 (95% CI: 0.33-0.45)。不同脑卒中亚型的PPV分别为:缺血性脑卒中(AIS)的0.83 (95% CI: 0.71-0.92)、未指定脑卒中的0.57 (95% CI: 0.37-0.76)、脑出血(ICH)的0.42 (95% CI: 0.33-0.52)、脑静脉血栓形成和蛛网膜下腔出血(SAH)的0.31 (95% CI: 0.55-0.98)和0.07 (95% CI: 0.01-0.22)。大多数未确诊的脑出血和SAH诊断发生在外伤性颅内出血的儿童中(分别为36%和66%)。在70例AIS确诊病例中,25例(36%)在非AIS编码组中被发现。不同中风定义的PPV差异显著,AHA/ASA定义的PPV最高(PPV = 0.39, 95% CI: 0.34-0.45), WHO定义的PPV最低(PPV = 0.29, 95% CI: 0.24-0.34)。相应地,儿童AIS的发生率从AHA/ASA定义的每10万人年1.5例变为ICD-11的1.2例和who定义的1.0例。总体判读一致性极佳(κ=0.85)。结论:经过验证,在DNRP中登记的具有卒中特异性诊断的儿童中,只有一半被确诊为卒中。在小儿卒中研究中应谨慎使用未经验证的行政数据。小儿中风的发病率可能会因中风定义的不同而有显著差异。
{"title":"The Positive Predictive Value of Pediatric Stroke Diagnoses in Administrative Data: A Retrospective Validation Study.","authors":"Julie Brix Bindslev,&nbsp;Soeren Paaske Johnsen,&nbsp;Klaus Hansen,&nbsp;Jan Brink Valentin,&nbsp;Christina Engel Hoei-Hansen,&nbsp;Thomas Truelsen","doi":"10.2147/CLEP.S414913","DOIUrl":"https://doi.org/10.2147/CLEP.S414913","url":null,"abstract":"<p><strong>Background: </strong>This retrospective cohort study aimed to examine the positive predictive value (PPV) of pediatric stroke diagnoses in the Danish National Registry of Patients (DNRP) and the impact of different stroke definitions on the PPV.</p><p><strong>Methods: </strong>We included children registered with a stroke or stroke-related diagnosis in the DNRP between January 2017 through December 2020. Two assessors reviewed medical records and validated cases according to the American Heart and American Stroke Association (AHA/ASA) stroke definition. The level of interrater agreement was examined using kappa statistics. Validation by the AHA/ASA definition was compared with validation according to the definition in the International Classification of Disease 11th version (ICD-11) and the World Health Organization's definition.</p><p><strong>Results: </strong>Stroke was confirmed in 120 of 309 included children, yielding an overall PPV of 0.39 (95% CI: 0.33-0.45). PPV varied across stroke subtypes from 0.83 (95% CI: 0.71-0.92) for ischemic stroke (AIS), 0.57 (95% CI: 0.37-0.76) for unspecified stroke, 0.42 (95% CI: 0.33-0.52) for intracerebral hemorrhage (ICH) to 0.31 (95% CI: 0.55-0.98) and 0.07 (95% CI: 0.01-0.22) for cerebral venous thrombosis and subarachnoid hemorrhage (SAH), respectively. Most non-confirmed ICH and SAH diagnoses were in children with traumatic intracranial hemorrhages (36 and 66% respectively). Among 70 confirmed AIS cases, 25 (36%) were identified in non-AIS code groups. PPV varied significantly across stroke definitions with the highest for the AHA/ASA definition (PPV = 0.39, 95% CI: 0.34-0.45) and the lowest for the WHO definition (PPV = 0.29, 95% CI: 0.24-0.34). Correspondingly, the incidence of pediatric AIS per 100.000 person-years changed from 1.5 for the AHA/ASA definition to 1.2 for ICD-11 and 1.0 for the WHO-definition. The overall interrater agreement was considered excellent (κ=0.85).</p><p><strong>Conclusion: </strong>After validation, stroke was confirmed in only half of the children registered in the DNRP with a stroke-specific diagnosis. Non-validated administrative data should be used with caution in pediatric stroke research. Pediatric stroke incidence rates may vary markedly depending on which stroke definition is used.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/6d/clep-15-755.PMC10290464.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study. 非选择性β受体阻滞剂与肝硬化和腹水患者败血症风险:一项大型观察性研究的结果。
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S400399
Morten Daniel Jensen, Hugh Watson, Hendrik Vilstrup, Peter Jepsen

Background and aims: Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk.

Methods: Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region.

Results: Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8-8.6) in baseline NSBB users vs 11.6% (95% CI 7.0-15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3-0.8) and after adjustment to 0.7 (95% CI 0.4-1.3).

Conclusion: NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.

背景和目的:先前的研究未能确定非选择性β受体阻滞剂(NSBB)是否能降低肝硬化败血症的风险。我们的目的是通过1198例肝硬化和腹水患者的数据来检验这个问题,这些数据包括在沙他伐坦的临床研究中,沙他伐坦是一种抗利尿激素受体拮抗剂,对感染风险没有影响。方法:评估NSBB使用者与非使用者的败血症风险。在为期一年的试验期间,每四周对患者进行一次检查,或与住院有关。我们计算了在基线时使用NSBB和未使用NSBB的患者的败血症累积风险。我们使用Cox回归比较当前使用者和非使用者之间败血症的危险率,考虑NSBB使用随时间的变化。我们调整了患者的性别和年龄、MELD-Na评分、白蛋白、抗生素的使用、质子泵抑制剂的使用、肝硬化病因、静脉曲张出血或收缩压史、腹水和HE的严重程度、HCC、其他癌症和糖尿病,同时按地理区域分层。结果:1198例患者中,54%的患者曾使用过NSBB。56例败血症发作。基线NSBB使用者的1年脓毒症风险降至5.7%(95%可信区间[CI] 2.8-8.6),而基线非使用者的1年脓毒症风险降至11.6%(95%可信区间[CI] 7.0-15.9)。目前NSBB使用者与目前非使用者败血症的危险比降至0.5 (95% CI 0.3-0.8),调整后降至0.7 (95% CI 0.4-1.3)。结论:使用NSBB可降低肝硬化和腹水患者败血症的风险,但估计的准确性受到败血症发作次数的限制。
{"title":"Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study.","authors":"Morten Daniel Jensen,&nbsp;Hugh Watson,&nbsp;Hendrik Vilstrup,&nbsp;Peter Jepsen","doi":"10.2147/CLEP.S400399","DOIUrl":"https://doi.org/10.2147/CLEP.S400399","url":null,"abstract":"<p><strong>Background and aims: </strong>Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk.</p><p><strong>Methods: </strong>Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region.</p><p><strong>Results: </strong>Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8-8.6) in baseline NSBB users vs 11.6% (95% CI 7.0-15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3-0.8) and after adjustment to 0.7 (95% CI 0.4-1.3).</p><p><strong>Conclusion: </strong>NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/e0/clep-15-775.PMC10290839.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9718029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Statin Use and Predictors of Statin Initiation Among Patients with Alcohol-Related Cirrhosis - A Danish Nationwide Cohort Study. 他汀类药物在酒精相关性肝硬化患者中的应用及开始使用的预测因素——一项丹麦全国队列研究
IF 3.9 2区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.2147/CLEP.S401862
Marine Sølling Ramsing, Frederik Kraglund, Peter Jepsen

Purpose: Statins reportedly increase the survival of patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis), but this association might be confounded by socioeconomic status. We examined the prevalence of statin use and socioeconomic and demographic predictors of statin initiation and discontinuation among patients with ALD cirrhosis.

Patients and methods: Using Danish nationwide healthcare registries, we examined statin use among patients diagnosed with ALD cirrhosis in 1997-2018. We computed the prevalence of statin use and incidence of statin initiation and discontinuation, and we used multivariable Cox regression to identify predictors of statin initiation and discontinuation.

Results: We identified 28,260 patients with ALD cirrhosis in 1997-2018. During this period, the prevalence of statin use rose sharply, reaching 19.0% in late 2018. Among patients diagnosed with ALD cirrhosis after 2010, 16.9% were using statins when they were diagnosed with cirrhosis. Among the patients who did not use statins initially, those with lower educational attainment were more likely to begin taking them than those with higher attainment. Also, cohabiting patients were more likely to begin than patients who lived alone, and employed patients were more likely to begin compared to patients outside the labour force. Among current statin users, unemployment predicted statin discontinuation.

Conclusion: The use of statins has become increasingly prevalent among Danish patients with ALD cirrhosis, reaching 19.0% in 2018. Employment, cohabitation, and a short education predicted statin initiation after ALD cirrhosis diagnosis, and unemployment predicted statin discontinuation. Overall, statin use was not a marker of a high socioeconomic status.

目的:据报道,他汀类药物可提高酒精相关性肝病(ALD肝硬化)肝硬化患者的生存率,但这种关联可能因社会经济地位而混淆。我们检查了他汀类药物在ALD肝硬化患者中使用的流行程度以及他汀类药物开始和停药的社会经济和人口学预测因素。患者和方法:使用丹麦全国医疗保健登记处,研究了1997-2018年诊断为ALD肝硬化的患者使用他汀类药物的情况。我们计算了他汀类药物使用的患病率和他汀类药物起始和停药的发生率,并使用多变量Cox回归来确定他汀类药物起始和停药的预测因子。结果:1997-2018年,我们确定了28,260例ALD肝硬化患者。在此期间,他汀类药物的使用率急剧上升,在2018年底达到19.0%。在2010年后诊断为ALD肝硬化的患者中,16.9%的患者在诊断为肝硬化时使用他汀类药物。在最初没有使用他汀类药物的患者中,受教育程度较低的患者比受教育程度较高的患者更有可能开始服用他汀类药物。此外,同居的患者比独居的患者更有可能开始,有工作的患者比没有工作的患者更有可能开始。在目前的他汀类药物使用者中,失业预示着他汀类药物的停药。结论:他汀类药物的使用在丹麦ALD肝硬化患者中越来越普遍,2018年达到19.0%。工作、同居和短暂教育预示着ALD肝硬化诊断后他汀类药物的开始使用,失业预示着他汀类药物的停止使用。总的来说,他汀类药物的使用并不是高社会经济地位的标志。
{"title":"Prevalence of Statin Use and Predictors of Statin Initiation Among Patients with Alcohol-Related Cirrhosis - A Danish Nationwide Cohort Study.","authors":"Marine Sølling Ramsing,&nbsp;Frederik Kraglund,&nbsp;Peter Jepsen","doi":"10.2147/CLEP.S401862","DOIUrl":"https://doi.org/10.2147/CLEP.S401862","url":null,"abstract":"<p><strong>Purpose: </strong>Statins reportedly increase the survival of patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis), but this association might be confounded by socioeconomic status. We examined the prevalence of statin use and socioeconomic and demographic predictors of statin initiation and discontinuation among patients with ALD cirrhosis.</p><p><strong>Patients and methods: </strong>Using Danish nationwide healthcare registries, we examined statin use among patients diagnosed with ALD cirrhosis in 1997-2018. We computed the prevalence of statin use and incidence of statin initiation and discontinuation, and we used multivariable Cox regression to identify predictors of statin initiation and discontinuation.</p><p><strong>Results: </strong>We identified 28,260 patients with ALD cirrhosis in 1997-2018. During this period, the prevalence of statin use rose sharply, reaching 19.0% in late 2018. Among patients diagnosed with ALD cirrhosis after 2010, 16.9% were using statins when they were diagnosed with cirrhosis. Among the patients who did not use statins initially, those with lower educational attainment were more likely to begin taking them than those with higher attainment. Also, cohabiting patients were more likely to begin than patients who lived alone, and employed patients were more likely to begin compared to patients outside the labour force. Among current statin users, unemployment predicted statin discontinuation.</p><p><strong>Conclusion: </strong>The use of statins has become increasingly prevalent among Danish patients with ALD cirrhosis, reaching 19.0% in 2018. Employment, cohabitation, and a short education predicted statin initiation after ALD cirrhosis diagnosis, and unemployment predicted statin discontinuation. Overall, statin use was not a marker of a high socioeconomic status.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/cc/clep-15-435.PMC10076903.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9265687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Epidemiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1